Trexquant Investment’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Trexquant Investment’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13,555	Closed	-$355K	–	1877
2022 Q4	$355K	Buy	+13,555	New	+$300K	0.01%	1045
2022 Q2	–	Sell	-12,405	Closed	-$203K	–	1970
2022 Q1	$203K	Buy	+12,405	New	+$169K	0.01%	1197
2021 Q4	–	Sell	-29,537	Closed	-$377K	–	1732
2021 Q3	$377K	Buy	+29,537	New	+$389K	0.03%	649
2017 Q4	–	Sell	-3,294	Closed	-$175K	–	1305
2017 Q3	$175K	Buy	+3,294	New	+$196K	0.04%	668
2016 Q3	–	Sell	-9,579	Closed	-$542K	–	1071
2016 Q2	$542K	Buy	+9,579	New	+$582K	0.07%	452

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Trexquant Investment's KDNY Position: Q1 2023 in Review

Trexquant Investment sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2023, closing a stake of 13,555 shares — an estimated $355K sold.

Trexquant Investment first reported a position in KDNY in Q2 2016 and held it in 5 quarters. The position peaked at $542K in Q2 2016. 157 funds tracked by Wall St. Rank hold KDNY as of Q1 2023.

Trexquant Investment reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Trexquant Investment sold 13,555 Chinook Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $355K.
Trexquant Investment first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2016 and held it in 5 quarters.
Trexquant Investment's Chinook Therapeutics, Inc. Common Stock position peaked at $542K in Q2 2016.
157 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Trexquant Investment's 13F filing for Q1 2023, filed 15 May 2023.